1. Home
  2. AMST vs TCRT Comparison

AMST vs TCRT Comparison

Compare AMST & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amesite Inc.

AMST

Amesite Inc.

HOLD

Current Price

$1.41

Market Cap

8.2M

Sector

Technology

ML Signal

HOLD

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

HOLD

Current Price

$2.98

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMST
TCRT
Founded
2017
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
6.7M
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
AMST
TCRT
Price
$1.41
$2.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.3M
12.6K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
40.46
24.66
EPS
N/A
N/A
Revenue
$110,459.00
$15,900,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$1.67
52 Week High
$4.78
$5.48

Technical Indicators

Market Signals
Indicator
AMST
TCRT
Relative Strength Index (RSI) 49.56 59.23
Support Level $0.83 $2.39
Resistance Level $2.07 $3.10
Average True Range (ATR) 0.31 0.17
MACD 0.07 0.06
Stochastic Oscillator 34.21 73.38

Price Performance

Historical Comparison
AMST
TCRT

About AMST Amesite Inc.

Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.

Share on Social Networks: